ArticleBMC gastroenterology2026
Primary biliary cholangitis with inflammation involving zone 3 of the liver has a poor response to ursodeoxycholic acid treatment: a retrospective cohort study.
Article in BMC gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundPrimary biliary cholangitis (PBC) is a chronic, progressive autoimmune disease characterized by the destruction of intrahepatic biliary epithelial cells, progressive fibrosis, and the expression of anti-mitochondrial antibodies. Although ursodeoxycholic acid (UDCA) can significantly improve liver biochemical parameters and delay disease progression as a first-line treatment, 40% of patients still have a poor response to UDCA treatment. Inflammation involving different regions of the hepatic lobule may be related to the therapeutic effect of UDCA. The aim of this study is to investigate the relationship between liver inflammation zones and UDCA treatment response in PBC patients, and to further analyze the predictive value of liver lobular zones for treatment response.
methodsThis is a single-center retrospective cohort study. A total of 121 PBC patients diagnosed in the Second Affiliated Hospital of Kunming Medical University from December 2014 to March 2024 were enrolled. Drawing on the Rappaport hepatic acinar zoning model and combining with the Bahar Halpern theory, the liver lobules were divided into three regions. The relationship between different divisions of liver lobules involved in PBC and the therapeutic effect of UDCA was studied, and the Nakanuma grading system was applied to evaluate the histological features. logistic regression analysis was used to investigate the association between lobular regions involved and non-response to UDCA treatment.
resultsIn univariate analysis, gender, jaundice, ascites and lesion involvement were statistically significant (P < 0.05), and these factors may be independent risk factors for non-response to UDCA.Lesions zone 3 involvement (the area around the central vein) were significantly associated with a poor response to UDCA treatment (OR: 3.632, CI95%: 1.130-11.677, P = 0.030). In addition, the presence of ascites at baseline was also an important risk factor for poor response to UDCA treatment (OR: 5.475, CI95%: 1.221–24.551, P = 0.026).
conclusionsThe pathological changes involving zone 3 of the hepatic lobule may be an important pathological marker for predicting the poor response of PBC patients to UDCA.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.